CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Irinotecan +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03279237
NCT03279237Phase 1Completed
CompareCT.gov

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Massachusetts General Hospital·interventional·Posted Sep 12, 2017·Updated May 18, 2026

In Brief

A Phase 1 clinical trial evaluating Irinotecan, Oxaliplatin, and 5 other interventions for GastroEsophageal Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer. The interventions involved in this study are: -FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Paclitaxel * Carboplatin * Proton Beam Radiation Therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroEsophageal Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 12, 2017
Enrollment StartOct 24, 2017
Primary CompletionSep 26, 2018
Study CompletionApr 1, 2026
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.8 years ago

Interventions

Irinotecandrug

May help shrink tumor before surgery.

Oxaliplatindrug

May help shrink tumor before surgery.

Leucovorindrug

May help shrink tumor before surgery.

5-Fluorouracildrug

May help shrink tumor before surgery.

Paclitaxeldrug

Paclitaxel may stop cancer cells from growing and spreading.

Radiation Therapyradiation

May help shrink tumor.

Carboplatindrug

Carboplatin may stop cancer cells from growing.